Amneal Pharmaceuticals マネジメント

マネジメント基準チェック /44

Amneal Pharmaceuticalsの CEO はChirag Patelで、 Jan2005年に任命され、の在任期間は 19.83年です。の年間総報酬は$ 2.37Mで、 31.6%給与と68.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の7.04%を直接所有しており、その価値は€ 186.40M 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と6.5年です。

主要情報

Chirag Patel

最高経営責任者

US$2.4m

報酬総額

CEO給与比率	31.6%
CEO在任期間	19.8yrs
CEOの所有権	7.0%
経営陣の平均在職期間	5.3yrs
取締役会の平均在任期間	6.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Amneal Pharmaceuticals の収益と比較して、Chirag Patel の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$184m
Jun 30 2024	n/a	n/a	-US$175m
Mar 31 2024	n/a	n/a	-US$169m
Dec 31 2023	US$2m	US$750k	-US$84m
Sep 30 2023	n/a	n/a	US$10m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$135m
Dec 31 2022	US$5m	US$750k	-US$130m
Sep 30 2022	n/a	n/a	-US$132m
Jun 30 2022	n/a	n/a	-US$134m
Mar 31 2022	n/a	n/a	US$2m
Dec 31 2021	US$5m	US$724k	US$11m
Sep 30 2021	n/a	n/a	US$14m
Jun 30 2021	n/a	n/a	US$9m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$2m	US$1	US$91m
Sep 30 2020	n/a	n/a	US$62m
Jun 30 2020	n/a	n/a	-US$194m
Mar 31 2020	n/a	n/a	-US$199m
Dec 31 2019	US$446k	US$44k	-US$362m
Sep 30 2019	n/a	n/a	-US$339m
Jun 30 2019	n/a	n/a	-US$67m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$325k	n/a	-US$21m

報酬と市場: Chiragの総報酬 ($USD 2.37M ) は、 German市場 ($USD 1.95M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Chiragの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Chirag Patel (57 yo)

19.8yrs

在職期間

US$2,370,385

報酬

Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Chirag Patel	Co-Founder	19.8yrs	US$2.37m	7.04% € 186.4m
Chintu Patel	Co-Founder	22.8yrs	US$2.37m	8.16% € 216.2m
Anastasios Konidaris	Executive VP & CFO	4.7yrs	US$1.89m	0.17% € 4.5m
Jason Daly	Senior VP	2.8yrs	US$1.35m	0.019% € 490.6k
Nikita Shah	Executive VP & Chief Human Resources Officer	10.8yrs	US$1.53m	0.094% € 2.5m
Andrew Boyer	Executive VP & Chief Commercial Officer of Generics	6.8yrs	US$1.94m	0.083% € 2.2m
Anthony DiMeo	Head of Investor Relations	no data	データなし	データなし
Gregory Sgammato	Senior Vice President of Corporate Development	1.8yrs	データなし	データなし
Pranav Mehta	Senior VP of Strategic Sourcing & Supply Management	1.8yrs	データなし	データなし
Sanjay Jain	Chief Quality Officer	5.8yrs	データなし	データなし
Srinivas Kone	Senior VP & Chief Scientific Officer of Generics	4.8yrs	データなし	データなし
Stanley Fisher	Vice President & Head of Medical Affairs	no data	データなし	データなし

5.3yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: 2DTの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Chirag Patel	Co-Founder	19.8yrs	US$2.37m	7.04% € 186.4m
Chintu Patel	Co-Founder	22.8yrs	US$2.37m	8.16% € 216.2m
Paul Meister	Independent Chairman of the Board	5.3yrs	US$299.08k	0.24% € 6.2m
J. Buchi	Independent Director	6.5yrs	US$302.20k	0.085% € 2.2m
Ted Nark	Independent Director	6.5yrs	US$244.70k	0.097% € 2.6m
Shlomo Yanai	Independent Director	4.9yrs	US$254.70k	0.079% € 2.1m
Jeffrey George	Independent Director	4.9yrs	US$277.20k	0.087% € 2.3m
Gautam Patel	Director	6.5yrs	US$217.20k	0.66% € 17.5m
Deborah Autor	Independent Director	2.3yrs	US$267.04k	0.030% € 799.2k
Emily Alva	Independent Director	6.5yrs	US$217.20k	0.081% € 2.1m
John Kiely	Independent Director	4.9yrs	US$284.70k	0.083% € 2.2m

6.5yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: 2DTの取締役会は経験豊富であると考えられます ( 6.5年の平均在任期間)。

Amneal Pharmaceuticals マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Insider recently sold €703k worth of stock

Independent Director recently sold €236k worth of stock

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold €703k worth of stock

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant

Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold €236k worth of stock

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022)

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Second quarter 2023 earnings released: EPS: US$0.078 (vs US$0.80 loss in 2Q 2022)

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Insufficient new directors

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$0.86 loss per share (vs US$0.071 profit in FY 2021)

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Insufficient new directors

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

Third quarter 2022 earnings released: US$0.018 loss per share (vs US$0.028 loss in 3Q 2021)

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022

Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.098 profit in 2Q 2021)

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022

High number of new directors

Amneal Pharmaceuticals, Inc. Appoints Deborah M. Autor to Board of Directors

Amneal Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Amneal Pharmaceuticals, Inc. Announces Class Action Lawsuit Settlement Updates

Amneal Pharmaceuticals, Inc. Launches LYVISPAH for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)

First quarter 2022 earnings released: US$0.014 loss per share (vs US$0.045 profit in 1Q 2021)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)

Amneal Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Amneal Pharmaceuticals, Inc. Reports Asset Impairment Charges for the Three Months Ended December 31, 2021

マネジメント基準チェック /44